BOSTON, July 14, 2011 /PRNewswire/ -- Summer Street Research Partners announced today that Ling Wang, CFA, has joined the firm as senior biotechnology analyst, director. She will be focused on covering the biotechnology sector, continuing to build out the biotechnology sector for the firm. Ms. Wang joins the firm with years of equity research experience.
"We are very excited to welcome Ling to the research team at Summer Street. Ling is a proven analyst with extensive Wall Street experience," says Dr. Mark Landy, director of research for Summer Street Research. "We believe Ling will bring valuable insights and a unique perspective to our research product, which will benefit our clients."
Prior to joining Summer Street, Ms. Wang was a senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. since 2009. Prior to Brean Murray, she was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008. Prior to that, she was a research assistant in the life science group at Manning & Napier Advisors, Inc. (an investment firm with approximately $16 billion assets under management) from 2004 to 2006. Ms. Wang earned her undergraduate degree in biology from Beijing University. She also holds a master's degree in molecular pharmacology from Albert Einstein College of Medicine and an MBA degree in finance from Yale University.
"I'm very excited to join Summer Street," Ms. Wang says. "With their unique MCRI consulting network and their singular focus on the healthcare sector, I believe Summer Street is the right platform for me to add real value to institutional healthcare investors on important and timely topics."
About Summer Street Research, Inc.
Summer Street Research Partners is an investment banking, institutional equity research and trading firm that focuses exclusively on the healthcare sector. Our mission is to help our clients maximize returns by providi
|SOURCE Summer Street Research Partners|
Copyright©2010 PR Newswire.
All rights reserved